Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Volk, E. L.
Right arrow Articles by Schneider, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Volk, E. L.
Right arrow Articles by Schneider, E.
[Cancer Research 63, 5538-5543, September 1, 2003]
© 2003 American Association for Cancer Research


Regular Articles

Wild-Type Breast Cancer Resistance Protein (BCRP/ABCG2) is a Methotrexate Polyglutamate Transporter1

Erin L. Volk and Erasmus Schneider2

Wadsworth Center, New York State Department of Health, Albany, New York 12201, and the Department of Biomedical Sciences, School of Public Health, State University of New York at Albany, Albany, New York 12201

The existence of an ATP-dependent methotrexate (MTX) efflux mechanism has long been postulated; however, until recently, the molecular components were largely unknown. We have previously demonstrated a role for the ATP-binding cassette transporter breast cancer resistance protein (BCRP) in MTX resistance (Volk et al., Cancer Res., 62: 5035–5040, 2002). Resistance to this antifolate directly correlated with BCRP expression, and was reversible by the BCRP inhibitors fumitremorgin C and GF120918. Here, we provide evidence for BCRP as a MTX-transporter using an in vitro membrane vesicle system. Inside-out membrane vesicles were generated from both drug-selected and stably transfected cell lines expressing either wild-type (Arg482) or mutant (Gly482) variants of BCRP. In the presence of the wild-type variant of BCRP, transport of MTX into vesicles was ATP-dependent, osmotically sensitive, and inhibited by fumitremorgin C. In contrast, no transport was observed in vesicles containing the mutant form of BCRP. Wild-type BCRP appeared to have low affinity, but high capacity, for the transport of MTX, with an estimated Km of 680 µM and a Vmax of 2400 pmol/mg/min. MTX accumulation was greatly decreased by mitoxantrone, a known BCRP substrate, suggesting competition for transport. Furthermore, and in contrast to the multidrug resistance-associated proteins, BCRP also transported significant amounts of polyglutamylated MTX. Although transport gradually decreased as the polyglutamate chain length increased, both MTX-Glu2 and MTX-Glu3 were substrates for BCRP. Together, these data demonstrate that BCRP is a MTX and MTX-polyglutamate transporter and reveal a possible mechanism by which it confers resistance.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
I. Ifergan, G. Jansen, and Y. G. Assaraf
The Reduced Folate Carrier (RFC) Is Cytotoxic to Cells under Conditions of Severe Folate Deprivation: RFC AS A DOUBLE EDGED SWORD IN FOLATE HOMEOSTASIS
J. Biol. Chem., July 25, 2008; 283(30): 20687 - 20695.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Biol.Home page
J. M. Evans, J. P. Day, P. Cabrero, J. A. T. Dow, and S.-A. Davies
A new role for a classical gene: White transports cyclic GMP
J. Exp. Biol., March 15, 2008; 211(6): 890 - 899.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Nozaki, H. Kusuhara, T. Kondo, M. Iwaki, Y. Shiroyanagi, H. Nakayama, S. Horita, H. Nakazawa, T. Okano, and Y. Sugiyama
Species Difference in the Inhibitory Effect of Nonsteroidal Anti-Inflammatory Drugs on the Uptake of Methotrexate by Human Kidney Slices
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1162 - 1170.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
C. Q. Xia, N. Liu, G. T. Miwa, and L.-S. Gan
Interactions of Cyclosporin A with Breast Cancer Resistance Protein
Drug Metab. Dispos., April 1, 2007; 35(4): 576 - 582.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Chattopadhyay, R. G. Moran, and I. D. Goldman
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications
Mol. Cancer Ther., February 1, 2007; 6(2): 404 - 417.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
P. Breedveld, D. Pluim, G. Cipriani, F. Dahlhaus, M. A. J. van Eijndhoven, C. J. F. de Wolf, A. Kuil, J. H. Beijnen, G. L. Scheffer, G. Jansen, et al.
The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models
Mol. Pharmacol., January 1, 2007; 71(1): 240 - 249.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi
Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System.
Physiol Rev, October 1, 2006; 86(4): 1179 - 1236.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
L. Couture, J. A. Nash, and J. Turgeon
The ATP-Binding Cassette Transporters and Their Implication in Drug Disposition: A Special Look at the Heart.
Pharmacol. Rev., June 1, 2006; 58(2): 244 - 258.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
K. Meissner, B. Heydrich, G. Jedlitschky, H. Meyer zu Schwabedissen, I. Mosyagin, P. Dazert, L. Eckel, S. Vogelgesang, R. W. Warzok, M. Bohm, et al.
The ATP-binding Cassette Transporter ABCG2 (BCRP), a Marker for Side Population Stem Cells, Is Expressed in Human Heart
J. Histochem. Cytochem., February 1, 2006; 54(2): 215 - 221.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. Dai, Y. Chen, and W. F. Elmquist
Distribution of the Novel Antifolate Pemetrexed to the Brain
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 222 - 229.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Shafran, I. Ifergan, E. Bram, G. Jansen, I. Kathmann, G. J. Peters, R. W. Robey, S. E. Bates, and Y. G. Assaraf
ABCG2 Harboring the Gly482 Mutation Confers High-Level Resistance to Various Hydrophilic Antifolates
Cancer Res., September 15, 2005; 65(18): 8414 - 8422.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Wielinga, J. H. Hooijberg, S. Gunnarsdottir, I. Kathmann, G. Reid, N. Zelcer, K. van der Born, M. de Haas, I. van der Heijden, G. Kaspers, et al.
The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates
Cancer Res., May 15, 2005; 65(10): 4425 - 4430.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
C. Q. Xia, N. Liu, D. Yang, G. Miwa, and L.-S. Gan
EXPRESSION, LOCALIZATION, AND FUNCTIONAL CHARACTERISTICS OF BREAST CANCER RESISTANCE PROTEIN IN CACO-2 CELLS
Drug Metab. Dispos., May 1, 2005; 33(5): 637 - 643.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
I. Ifergan, G. Jansen, and Y. G. Assaraf
Cytoplasmic Confinement of Breast Cancer Resistance Protein (BCRP/ABCG2) as a Novel Mechanism of Adaptation to Short-Term Folate Deprivation
Mol. Pharmacol., April 1, 2005; 67(4): 1349 - 1359.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Z.-S. Chen, Y. Guo, M. G. Belinsky, E. Kotova, and G. D. Kruh
Transport of Bile Acids, Sulfated Steroids, Estradiol 17-{beta}-D-Glucuronide, and Leukotriene C4 by Human Multidrug Resistance Protein 8 (ABCC11)
Mol. Pharmacol., February 1, 2005; 67(2): 545 - 557.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Burger, H. van Tol, A. W. M. Boersma, M. Brok, E. A. C. Wiemer, G. Stoter, and K. Nooter
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump
Blood, November 1, 2004; 104(9): 2940 - 2942.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Breedveld, N. Zelcer, D. Pluim, O. Sonmezer, M. M. Tibben, J. H. Beijnen, A. H. Schinkel, O. van Tellingen, P. Borst, and J. H. M. Schellens
Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions
Cancer Res., August 15, 2004; 64(16): 5804 - 5811.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Gupta, Y. Zhang, J. D. Unadkat, and Q. Mao
HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)
J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 334 - 341.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Ifergan, A. Shafran, G. Jansen, J. H. Hooijberg, G. L. Scheffer, and Y. G. Assaraf
Folate Deprivation Results in the Loss of Breast Cancer Resistance Protein (BCRP/ABCG2) Expression: A ROLE FOR BCRP IN CELLULAR FOLATE HOMEOSTASIS
J. Biol. Chem., June 11, 2004; 279(24): 25527 - 25534.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. L. R. Ee, S. Kamalakaran, D. Tonetti, X. He, D. D. Ross, and W. T. Beck
Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein (ABCG2) Gene
Cancer Res., February 15, 2004; 64(4): 1247 - 1251.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.